Theralase Technologies Inc TLT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TLT is a good fit for your portfolio.
News
-
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
-
Theralase(R) Granted Canadian Cancer Vaccine Patent
-
Theralase(R) Release's 4Q2023 Interim Financial Statements
-
Theralase(R) to Host Advisory Board Meetings at Canadian Urological Association Bladder Cancer Forum and the American Urological Association
-
Theralase(R) Donates Cool Laser Therapy Technology to Aid in Research and Development of a Treatment for Parkinson's Disease
-
Dr. Michael Jewett Joins Theralase(R) to Help Complete Enrollment in the Phase II Non-Muscle Invasive Bladder Cancer Clinical Study
-
Theralase(R) Closes $CAN 1.2 Million Non-Brokered Private Placement
Trading Information
- Previous Close Price
- CAD 0.17
- Day Range
- CAD 0.16–0.17
- 52-Week Range
- CAD 0.16–0.31
- Bid/Ask
- CAD 0.16 / CAD 0.17
- Market Cap
- CAD 37.62 Mil
- Volume/Avg
- 65,575 / 133,598
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 32.88
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Core
- Total Number of Employees
- 14
- Website
- https://www.theralase.com
Valuation
|
Metric
|
TLT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 32.88 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
TLT
|
|---|---|
Quick Ratio | 0.60 |
Current Ratio | 1.39 |
Interest Coverage | −150.97 |
Quick Ratio
TLT
Profitability
|
Metric
|
TLT
|
|---|---|
Return on Assets (Normalized) | −115.95% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −155.77% |
Return on Assets
TLT
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Tmpzyxh | Ytffr | $185.4 Bil | |
SYK
| Stryker Corp | Fxnzxwfpl | Lwfp | $127.7 Bil | |
BSX
| Boston Scientific Corp | Cyhhtqj | Zgcdp | $107.6 Bil | |
MDT
| Medtronic PLC | Djwvzmbp | Vqydx | $105.9 Bil | |
DXCM
| DexCom Inc | Xjjhtkcfq | Yrtn | $54.7 Bil | |
EW
| Edwards Lifesciences Corp | Rndjqdnnl | Pvmscsv | $52.0 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Lwgptfdm | Hypzy | $24.6 Bil | |
ALGN
| Align Technology Inc | Mhcgxpw | Xhdmyrf | $23.4 Bil | |
PHG
| Koninklijke Philips NV ADR | Gzxhvpbd | Hdwslx | $18.7 Bil | |
PODD
| Insulet Corp | Xwcjwhlj | Tfnyzbg | $11.6 Bil |